/
Gastroenterology
Alcoholic Fatty Liver Disease
24
Pipeline Programs↗
34
Active Trials↗
37
Companies Involved↗
Alcoholic Fatty Liver Disease is an emerging landscape with 24 programs across 37 companies. The most active players are Akero Therapeutics, Hinova Pharmaceuticals Inc., Tasly Biopharmaceuticals Co., Ltd.. 4 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical13
Phase 26
Phase 34
Approved
No programs
Analysis
Modality Breakdown
77%
Small molecule
17 of 22 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 22 classified programs, each share of the total. Modality classified for 100% of 24 pipeline programs.
Analysis
Trial Status
187
clinical trials
Completed103 · 55%
Recruiting21 · 11%
Unknown status21 · 11%
Terminated19 · 10%
Withdrawn10 · 5%
Active, not recruiting7 · 4%
Other6 · 3%
Clinical Trials
Trial Activity
187 trials
Quantitation of Hepatic Mitochondrial Fluxes in Humans With Nonalcoholic Fatty Liver Disease (NAFLD)
Recruiting·TThe University of Texas Health Science Center at San Antonio·Approved·NCT05305287·60 enrolled
Page 1 of 13
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)